Fallopian Tube Cancer Trials
Select Clinical Trial
Protocol Number: NRG-GY005/ Ovarian/ Fallopian Tube/ Peritoneal
Protocol Title: Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Eligibility: Patient population 18 Years and older with confirmed ovarian cancer, peritoneal cancer or fallopian tube cancer that has returned after receiving chemotherapy with drugs that contain platinum (platinum-resistant) or continued to grow while being treated with platinum-based chemotherapy drugs (platinum-refractory).
Contact Information: (910) 715-2200
____________________________________________________________________________________________
Protocol Number: ImmunoGen/GOG 3045
Protocol Title: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
Eligibility: Women ≥ 18 years of age with a confirmed diagnosis of high-grade serous EOC, primary peritoneal cancer, or fallopian tube cancer. Patients must have platinum-resistant disease.
Contact Information: (910) 715-2200